Drug Trial Radar · NCT04632862
The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus.
Last checked: Nov 19, 2026Latest source record: Oct 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
140
Actual
Start
Nov 11, 2020
Primary completion
Nov 25, 2021
Study completion Nov 25, 2021
Sponsor
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.Industry
- Sponsor type
- Industry
- First posted
- Nov 17, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the efficacy and safety of DWP16001 compared to placebo in the treatment of type 2 diabetes mellitus.
Conditions
- T2DM (Type 2 Diabetes Mellitus)
Interventions
DWP16001Drug
DWP16001 A mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- HbA1c level at Week 24 after administration of the IPTime frame: at Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Daewoong pharmatceutical
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.